Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect: European Urology

F Pederzoli, M Bandini, A Briganti, ER Plimack, G Niegisch, EY Yu, A Bamias, N Agarwal, SS Sridhar, CN Sternberg, UN Vaishampayan, C Théodore, JE Rosenberg, LC Harshman, J Bellmunt, MD Galsky, A Gallina, A Salonia, F Montorsi, A Necchion behalf of the RISC Investigators

Research output: Contribution to journalArticle

Abstract

Adjuvant chemotherapy after neoadjuvant treatment and radical cystectomy for muscle-invasive bladder cancer should be offered only to patients with a high risk of 1-yr recurrence. Time-based endpoints may be more useful to help data interpretation for the next adjuvant and neoadjuvant immunotherapy studies. © 2019 European Association of Urology
Original languageEnglish
Pages (from-to)425-429
Number of pages5
JournalEuropean Urology
Volume76
Issue number4
DOIs
Publication statusPublished - 2019

Fingerprint Dive into the research topics of 'Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect: European Urology'. Together they form a unique fingerprint.

  • Cite this

    Pederzoli, F., Bandini, M., Briganti, A., Plimack, ER., Niegisch, G., Yu, EY., Bamias, A., Agarwal, N., Sridhar, SS., Sternberg, CN., Vaishampayan, UN., Théodore, C., Rosenberg, JE., Harshman, LC., Bellmunt, J., Galsky, MD., Gallina, A., Salonia, A., Montorsi, F., ... Investigators, O. B. O. T. RISC. (2019). Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect: European Urology. European Urology, 76(4), 425-429. https://doi.org/10.1016/j.eururo.2019.06.032